Do you pursue screening beyond age-appropriate malignancy screening, especially in younger patients? For how long do you continue to monitor beyond th...
New answer by at The University of Chicago Medicine (August 29, 2024)
This is a great question and one that is very relevant to our clinical practice. Different myositis specific and associated antibodies seem to carry different risks in their a...